{"transactions":[{"id":712224,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-07-09T22:07:56.000Z","date":"2026-07-07","kind":"exercise","planned":true,"acquired":false,"shares":10111,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":47.11,"exercise_date":"2025-07-01","expiration_date":"2034-06-30","underlying":"Common Stock","underlying_shares":10111},"source":{"system":"sec-edgar","filing":"0000874015-26-000237","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000237/edgardoc.xml","form_type":"4"}},{"id":712223,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-09T22:07:56.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":10111,"price":85.4156,"value":863637.1316,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.040 to $85.730 inclusive.  The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4."}],"balance_after":3811,"source":{"system":"sec-edgar","filing":"0000874015-26-000237","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000237/edgardoc.xml","form_type":"4"}},{"id":712222,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-09T22:07:56.000Z","date":"2026-07-07","kind":"exercise","planned":true,"acquired":true,"shares":10111,"price":47.11,"value":476329.21,"ownership":{"direct":true},"balance_after":13922,"source":{"system":"sec-edgar","filing":"0000874015-26-000237","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000237/edgardoc.xml","form_type":"4"}},{"id":716455,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-07-06T22:44:43.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":2301,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the fifth anniversary of the vesting date, the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the fifth anniversary of the vesting date, the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026."}],"balance_after":7521,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2301},"source":{"system":"sec-edgar","filing":"0000874015-26-000227","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000227/edgardoc.xml","form_type":"4"}},{"id":716454,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-07-06T22:44:43.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":5369,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026."}],"balance_after":5369,"derivative":{"exercise_price":79.19,"exercise_date":"2027-07-01","expiration_date":"2036-06-30","underlying":"Common Stock","underlying_shares":5369},"source":{"system":"sec-edgar","filing":"0000874015-26-000227","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000227/edgardoc.xml","form_type":"4"}},{"id":859791,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-03-05T23:14:15.000Z","date":"2026-03-03","kind":"exercise","planned":true,"acquired":false,"shares":10321,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":41.08,"exercise_date":"2024-07-03","expiration_date":"2033-07-02","underlying":"Common Stock","underlying_shares":10321},"source":{"system":"sec-edgar","filing":"0000874015-26-000136","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000136/edgardoc.xml","form_type":"4"}},{"id":859790,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-03-05T23:14:15.000Z","date":"2026-03-03","kind":"exercise","planned":true,"acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":40.05,"exercise_date":"2022-06-02","expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000874015-26-000136","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000136/edgardoc.xml","form_type":"4"}},{"id":859789,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-03-05T23:14:15.000Z","date":"2026-03-03","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":38.06,"exercise_date":"2023-07-01","expiration_date":"2032-06-30","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000874015-26-000136","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000136/edgardoc.xml","form_type":"4"}},{"id":859788,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-05T23:14:15.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":1005,"price":80.799,"value":81202.995,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.61 to $81.01 inclusive.  The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4."}],"balance_after":3811,"source":{"system":"sec-edgar","filing":"0000874015-26-000136","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000136/edgardoc.xml","form_type":"4"}},{"id":859787,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-05T23:14:15.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":14608,"price":79.875,"value":1166814.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.57to $80.55 inclusive.  The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4."}],"balance_after":4816,"source":{"system":"sec-edgar","filing":"0000874015-26-000136","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000136/edgardoc.xml","form_type":"4"}},{"id":859786,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-05T23:14:15.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":39265,"price":79.114,"value":3106411.21,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.565 to $79.565 inclusive.  The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4."}],"balance_after":19424,"source":{"system":"sec-edgar","filing":"0000874015-26-000136","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000136/edgardoc.xml","form_type":"4"}},{"id":859785,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-05T23:14:15.000Z","date":"2026-03-03","kind":"exercise","planned":true,"acquired":true,"shares":18000,"price":40.05,"value":720900.0,"ownership":{"direct":true},"balance_after":58689,"source":{"system":"sec-edgar","filing":"0000874015-26-000136","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000136/edgardoc.xml","form_type":"4"}},{"id":859784,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-05T23:14:15.000Z","date":"2026-03-03","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":38.06,"value":456720.0,"ownership":{"direct":true},"balance_after":40689,"source":{"system":"sec-edgar","filing":"0000874015-26-000136","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000136/edgardoc.xml","form_type":"4"}},{"id":859783,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-05T23:14:15.000Z","date":"2026-03-03","kind":"exercise","planned":true,"acquired":true,"shares":10321,"price":41.08,"value":423986.68,"ownership":{"direct":true},"balance_after":28689,"source":{"system":"sec-edgar","filing":"0000874015-26-000136","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401526000136/edgardoc.xml","form_type":"4"}},{"id":946484,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:54:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":56.5,"underlying":"Common Stock","underlying_shares":2200},"source":{"system":"sec-edgar","filing":"0001104659-26-001385","document":"tm261736-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001385/tm261736-11_4seq1.xml","form_type":"4"}},{"id":946483,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:54:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":734,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":216,"underlying":"Common Stock","underlying_shares":734},"source":{"system":"sec-edgar","filing":"0001104659-26-001385","document":"tm261736-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001385/tm261736-11_4seq1.xml","form_type":"4"}},{"id":946482,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:54:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":90.5,"underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001104659-26-001385","document":"tm261736-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001385/tm261736-11_4seq1.xml","form_type":"4"}},{"id":946481,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:54:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":416,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":161,"underlying":"Common Stock","underlying_shares":416},"source":{"system":"sec-edgar","filing":"0001104659-26-001385","document":"tm261736-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001385/tm261736-11_4seq1.xml","form_type":"4"}},{"id":946480,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:54:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1571,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":458.25,"underlying":"Common Stock","underlying_shares":1571},"source":{"system":"sec-edgar","filing":"0001104659-26-001385","document":"tm261736-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001385/tm261736-11_4seq1.xml","form_type":"4"}},{"id":946479,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:54:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2460,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."}],"balance_after":0,"derivative":{"exercise_price":9.0775,"underlying":"Common Stock","underlying_shares":2460},"source":{"system":"sec-edgar","filing":"0001104659-26-001385","document":"tm261736-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001385/tm261736-11_4seq1.xml","form_type":"4"}},{"id":946478,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:54:24.000Z","date":"2026-01-06","kind":"other","planned":false,"acquired":false,"shares":578,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-001385","document":"tm261736-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001385/tm261736-11_4seq1.xml","form_type":"4"}},{"id":1056281,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T21:23:52.000Z","date":"2025-08-22","kind":"sale","planned":true,"acquired":false,"shares":1427,"price":42.5278,"value":60687.1706,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 3, 2023"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.30 to $42.75 inclusive.  The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4."}],"balance_after":18368,"source":{"system":"sec-edgar","filing":"0000874015-25-000180","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401525000180/edgardoc.xml","form_type":"4"}},{"id":1085964,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-07-17T20:53:54.000Z","date":"2025-07-15","kind":"exercise","planned":false,"acquired":false,"shares":4079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."}],"balance_after":5220,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4079},"source":{"system":"sec-edgar","filing":"0000874015-25-000156","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401525000156/edgardoc.xml","form_type":"4"}},{"id":1085963,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-17T20:53:54.000Z","date":"2025-07-15","kind":"exercise","planned":false,"acquired":true,"shares":4079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."}],"balance_after":19795,"source":{"system":"sec-edgar","filing":"0000874015-25-000156","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401525000156/edgardoc.xml","form_type":"4"}},{"id":1096720,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-07-02T20:52:54.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":5220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025."}],"balance_after":9299,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5220},"source":{"system":"sec-edgar","filing":"0000874015-25-000137","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401525000137/edgardoc.xml","form_type":"4"}},{"id":1096719,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-07-02T20:52:54.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":11518,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025."}],"balance_after":11518,"derivative":{"exercise_price":39.94,"exercise_date":"2026-07-01","expiration_date":"2035-06-30","underlying":"Common Stock","underlying_shares":11518},"source":{"system":"sec-edgar","filing":"0000874015-25-000137","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401525000137/edgardoc.xml","form_type":"4"}},{"id":1111480,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:08.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":61500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2026 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":61500,"derivative":{"exercise_price":0.36,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":61500},"source":{"system":"sec-edgar","filing":"0001104659-25-059436","document":"tm2517941-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925059436/tm2517941-5_4seq1.xml","form_type":"4"}},{"id":1453175,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-07-17T21:02:35.000Z","date":"2024-07-15","kind":"exercise","planned":true,"acquired":false,"shares":4677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."}],"balance_after":4079,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4677},"source":{"system":"sec-edgar","filing":"0000874015-24-000178","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401524000178/edgardoc.xml","form_type":"4"}},{"id":1453174,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-17T21:02:35.000Z","date":"2024-07-16","kind":"sale","planned":true,"acquired":false,"shares":737,"price":50.17,"value":36975.29,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 3, 2023"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.0825 to $50.245 inclusive.  The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4."}],"balance_after":15716,"source":{"system":"sec-edgar","filing":"0000874015-24-000178","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401524000178/edgardoc.xml","form_type":"4"}},{"id":1453173,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-17T21:02:35.000Z","date":"2024-07-16","kind":"sale","planned":true,"acquired":false,"shares":900,"price":48.9379,"value":44044.11,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 3, 2023"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.745 to $49.461 inclusive.  The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4."}],"balance_after":16453,"source":{"system":"sec-edgar","filing":"0000874015-24-000178","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401524000178/edgardoc.xml","form_type":"4"}},{"id":1453172,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-17T21:02:35.000Z","date":"2024-07-15","kind":"exercise","planned":true,"acquired":true,"shares":4677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."}],"balance_after":17353,"source":{"system":"sec-edgar","filing":"0000874015-24-000178","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401524000178/edgardoc.xml","form_type":"4"}},{"id":1461381,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-07-03T18:47:10.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":4079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant on July 1, 2024 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Grant on July 1, 2024 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2024."}],"balance_after":8756,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4079},"source":{"system":"sec-edgar","filing":"0000874015-24-000160","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401524000160/edgardoc.xml","form_type":"4"}},{"id":1461380,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-07-03T18:47:10.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":10111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024."}],"balance_after":10111,"derivative":{"exercise_price":47.11,"exercise_date":"2025-07-01","expiration_date":"2034-06-30","underlying":"Common Stock","underlying_shares":10111},"source":{"system":"sec-edgar","filing":"0000874015-24-000160","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401524000160/edgardoc.xml","form_type":"4"}},{"id":1481971,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-12T20:51:43.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2025 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":55000,"derivative":{"exercise_price":2.26,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-24-070895","document":"tm2417031-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924070895/tm2417031-3_4seq1.xml","form_type":"4"}},{"id":1817076,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-03T21:20:57.000Z","date":"2023-08-01","kind":"sale","planned":true,"acquired":false,"shares":657,"price":41.05,"value":26969.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on April 26, 2023"}],"balance_after":12676,"source":{"system":"sec-edgar","filing":"0000874015-23-000181","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401523000181/edgardoc.xml","form_type":"4"}},{"id":1827333,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-07-19T22:05:30.000Z","date":"2023-07-17","kind":"exercise","planned":false,"acquired":false,"shares":5333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."}],"balance_after":4677,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5333},"source":{"system":"sec-edgar","filing":"0000874015-23-000173","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401523000173/edgardoc.xml","form_type":"4"}},{"id":1827332,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-19T22:05:30.000Z","date":"2023-07-17","kind":"exercise","planned":false,"acquired":true,"shares":5333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."}],"balance_after":13333,"source":{"system":"sec-edgar","filing":"0000874015-23-000173","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401523000173/edgardoc.xml","form_type":"4"}},{"id":1834552,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-07-06T21:14:06.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":4677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2023 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant on July 3, 2023 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 3, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Grant on July 3, 2023 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 3, 2023."}],"balance_after":10010,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4677},"source":{"system":"sec-edgar","filing":"0000874015-23-000155","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401523000155/edgardoc.xml","form_type":"4"}},{"id":1834551,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-07-06T21:14:06.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":10321,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2023 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant on July 3, 2023 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 3, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Grant on July 3, 2023 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 3, 2023."}],"balance_after":10321,"derivative":{"exercise_price":41.08,"exercise_date":"2024-07-03","expiration_date":"2033-07-02","underlying":"Common Stock","underlying_shares":10321},"source":{"system":"sec-edgar","filing":"0000874015-23-000155","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401523000155/edgardoc.xml","form_type":"4"}},{"id":1858675,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T20:19:20.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":18355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":18355,"derivative":{"exercise_price":8.64,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":18355},"source":{"system":"sec-edgar","filing":"0001104659-23-070364","document":"tm2318463-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923070364/tm2318463-6_4seq1.xml","form_type":"4"}},{"id":1858674,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T20:19:20.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":14467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award.  Each RSU represents the contingent right to receive one share of Common Stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":14467,"source":{"system":"sec-edgar","filing":"0001104659-23-070364","document":"tm2318463-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923070364/tm2318463-6_4seq1.xml","form_type":"4"}},{"id":2205785,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-07-19T23:20:17.000Z","date":"2022-07-15","kind":"exercise","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company."}],"balance_after":5333,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0000874015-22-000137","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401522000137/edgardoc.xml","form_type":"4"}},{"id":2205784,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-19T23:20:17.000Z","date":"2022-07-15","kind":"exercise","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0000874015-22-000137","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401522000137/edgardoc.xml","form_type":"4"}},{"id":2213210,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-07-06T21:23:19.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":5333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant on July 1, 2022 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Grant on July 1, 2022 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2022."}],"balance_after":13333,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5333},"source":{"system":"sec-edgar","filing":"0000874015-22-000119","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401522000119/edgardoc.xml","form_type":"4"}},{"id":2213209,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-07-06T21:23:19.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant on July 1, 2022 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Grant on July 1, 2022 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2022."}],"balance_after":12000,"derivative":{"exercise_price":38.06,"exercise_date":"2023-07-01","expiration_date":"2032-06-30","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000874015-22-000119","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401522000119/edgardoc.xml","form_type":"4"}},{"id":2235786,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T20:19:54.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2023 Annual Meeting of Stockholders of Mersana Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":3.62,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-22-070141","document":"tm2218135-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922070141/tm2218135-4_4seq1.xml","form_type":"4"}},{"id":2443718,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T22:02:25.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":10416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2022."}],"balance_after":10416,"derivative":{"exercise_price":6.44,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":10416},"source":{"system":"sec-edgar","filing":"0001104659-22-001553","document":"tm221771-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922001553/tm221771-2_4seq1.xml","form_type":"4"}},{"id":2631118,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-07-20T00:13:20.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant of July 15, 2021 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 15, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Grant of July 15, 2021 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 15, 2021."}],"balance_after":8000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0000874015-21-000133","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401521000133/edgardoc.xml","form_type":"4"}},{"id":2642518,"issuer":{"id":1182,"kind":"organization","name":"IONIS PHARMACEUTICALS INC","symbol":"IONS"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-07-06T21:51:18.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant of July 1, 2021 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on June 2, 2022. The option is exercisable to 0 shares on July 1, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Grant of July 1, 2021 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on June 2, 2022. The option is exercisable to 0 shares on July 1, 2021."}],"balance_after":18000,"derivative":{"exercise_price":40.05,"exercise_date":"2022-06-02","expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000874015-21-000111","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/874015/000087401521000111/edgardoc.xml","form_type":"4"}},{"id":2680936,"issuer":{"id":130904,"kind":"organization","name":"Allena Pharmaceuticals, Inc.","symbol":"ALNA"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T16:00:19.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":37000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of stockholders."}],"balance_after":37000,"derivative":{"exercise_price":1.14,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":37000},"source":{"system":"sec-edgar","filing":"0001209191-21-038170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1624658/000120919121038170/doc4.xml","form_type":"4"}},{"id":2794492,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-11T22:01:49.000Z","date":"2021-03-09","kind":"grant","acquired":true,"shares":39275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments over three years from the date of the grant."}],"balance_after":39275,"derivative":{"exercise_price":18.33,"expiration_date":"2031-03-08","underlying":"Common Stock","underlying_shares":39275},"source":{"system":"sec-edgar","filing":"0001104659-21-035074","document":"tm219431-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465921035074/tm219431-2_4seq1.xml","form_type":"4"}},{"id":2975196,"issuer":{"id":130904,"kind":"organization","name":"Allena Pharmaceuticals, Inc.","symbol":"ALNA"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-18T16:14:48.000Z","date":"2020-11-17","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders."}],"balance_after":14000,"derivative":{"exercise_price":1.45,"expiration_date":"2030-11-16","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001209191-20-059065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1624658/000120919120059065/doc4.xml","form_type":"4"}},{"id":3536485,"issuer":{"id":130904,"kind":"organization","name":"Allena Pharmaceuticals, Inc.","symbol":"ALNA"},"owners":[{"id":31320,"kind":"person","name":"Diaz Allene M.","position":1,"cik":"0001773314","reported_name":"Diaz Allene M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-07T09:18:41.000Z","date":"2019-05-06","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock option shall vest ratably over three years in annual installments beginning on April 15, 2019."}],"balance_after":28000,"derivative":{"exercise_price":6.42,"expiration_date":"2029-05-05","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001209191-19-027895","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1624658/000120919119027895/doc4.xml","form_type":"4"}}]}